ARA-290 vs Thymalin

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Thymic peptide bioregulator; restores thymic function and T-cell production; modulates cytokine balance; shown to extend lifespan in animal models

Thymalin is a polypeptide preparation and Khavinson-class bioregulator derived from thymic tissue, proposed to restore age-related immune dysfunction associated with thymic involution by supplying thymic hormonal signals that support T-lymphocyte differentiation, immune homeostasis, and immunological reserve in elderly subjects. As a thymic bioregulator, thymalin is proposed to modulate gene expression in aging lymphoid cells through peptide-chromatin interactions and to support thymopoiesis and T-cell maturation in subjects whose endogenous thymic output has declined with age-associated involution. Published observational research from the Khavinson laboratory documented that long-term supplementation with thymalin and related thymic and pineal peptides was associated with significantly reduced all-cause mortality in elderly cohorts over extended follow-up, and earlier work reported geroprotective effects of thymalin and epithalamin in Russian geriatric research populations. Thymalin is not FDA-approved; it is available as a clinical preparation in Russia, where it has regulatory approval for immune support in elderly patients, and its evidence base derives from Russian-origin observational and preclinical studies with limited independent replication by international standards. Thymalin benefits investigated in preclinical and clinical research include immune system restoration in aged subjects, improved T-lymphocyte counts and function, modulation of cytokine balance toward anti-inflammatory profiles, and partial reversal of age-associated thymic involution. Long-term studies in aged animal models have documented lifespan extension with thymalin administration, and observational research in elderly human cohorts using thymic peptide preparations has associated treatment with reduced all-cause mortality over multiyear follow-up periods — findings published in Russian medical literature. As a thymic bioregulator, thymalin is proposed to work by restoring the hormonal output of the aging thymus rather than by immunosuppression or direct cytokine administration, distinguishing it from synthetic immunomodulatory drugs. Research interest also includes thymalin for age-related infections susceptibility, autoimmune regulation, and overall immune resilience as part of longevity-focused bioregulator protocols.